Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus

Gene Therapy

Volumn 11, Issue 16, 2004, Pages 1256-1263

  Green, N K ^a   Herbert, C W ^a   Hale, S J ^b   Hale, A B ^a   Mautner, V ^c   Harkins, R ^d   Hermiston, T ^d   Ulbrich, K ^e   Fisher, K D ^b   Seymour, L W ^b  

^a Hybrid Systems Ltd   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d BAYER AG   (Germany)

^e INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Adenovirus; Gene delivery; Polymer coating

Indexed keywords

ADENOVIRUS VECTOR; AMINOTRANSFERASE; COPOLYMER; LUCIFERASE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; POLYMER; VIRUS RECEPTOR;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CIRCULATION TIME; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG TOXICITY; DRUG UPTAKE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE TARGETING; LIVER; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS PARTICLE; WEIGHT REDUCTION;

ADENOVIRIDAE; ANIMALS; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAVENOUS; LIVER; MICE; NEOPLASMS; PHAGOCYTOSIS; PLASMA; POLYMERS; RECEPTORS, VIRUS; RECOMBINATION, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; MURINAE;

EID: 4444374585     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302295     Document Type: Article

References (23)

1. Bergelson JM et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
2. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
3. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000; 268: 382-390.
4. Dechecchi MC et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
5. Bergelson JM et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 415-419.
6. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Therapy 2001; 8: 1347-1353.
7. Leissner P et al. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Therapy 2001; 8: 49-57.
8. Einfeld DA et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001; 75: 11284-11291.
9. Smith T et al. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 2002; 5: 770-779.
10. Smith TA et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003; 14: 777-787.
11. Tao N et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3: 28-35.
12. Fisher KD et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Therapy 2001; 8: 341-348.
13. Ye X, Jerebtsova M, Ray PE. Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther 2000; 11: 621-627.
14. Kasono K et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999; 5: 2571-2579.
15. Nicklin SA et al. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000; 102: 231-237.
16. Wickham TJ. Targeting adenovirus. Gene Therapy 2000; 7: 110-114.
17. Romanczuk H et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum Gene Ther 1999; 10: 2615-2626.
18. Drapkin PT et al. Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J Clin Invest 2000; 105: 589-596.
19. Cichon G et al. Titer determination of Ad5 in blood: a cautionary note. Gene Therapy 2003; 10: 1012-1017.
20. Reid T et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy 2001; 8: 1618-1626.
21. Nemunaitis J et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Therapy 2001; 8: 746-759.
22. Murakami P, McCaman MT. Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent dye. Anal Biochem 1999; 274: 283-288.
23. Rihova B et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 1989; 10: 335-342.